IP Verse

Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist

Patent No. EP4011915 (titled "Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist") was filed by Regeneron Pharmaceuticals on Aug 20, 2013. The application was issued on Nov 15, 2023.

Patent Summary

A method for treating obesity involves using a combination of two bacteria strains, Bifidobacterium longum subsp. longum (BL) and Akkermansia muciniphila (Ak), to modulate the gut microbiome and promote weight loss. The treatment involves administering a composition containing BL and Ak strains to obese individuals. The BL strain increases production of the hormone GLP-1, which reduces appetite and calorie intake. The Ak strain promotes degradation of mucus in the gut, which reduces energy harvest from food. By using a combination of these strains, the treatment aims to enhance weight loss and obesity management through multiple mechanisms.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HAMPTON KNOWLESJul 11, 2024D YOUNG
BOULT WADE TENNANTJul 10, 2024BOULT WADE TENNANT
SECERNAJul 10, 2024SECERNA
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBJul 8, 2024MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBB
DR H ULRICH DORRIESJul 3, 2024DORRIES
DR H ULRICH DORRIESJul 3, 2024DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN
LUIGIOct 11, 2023TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4011915

REGENERON PHARMACEUTICALS
Application Number
EP21199451A
Filing Date
Aug 20, 2013
Status
Granted And Under Opposition
Sep 8, 2023
Publication Date
Nov 15, 2023
External Links
Slate, Register , Google Patents